Catalyst overview
Research summary
This catalyst tracks a Phase 2 update for Lorundrostat in Obstructive sleep apnea, Hypertension. The expected timing is based on the latest available company guidance and may change.
11/10/25:- Completed enrollment reiterated; topline Explore-OSA Phase 2 data expected in Q1 2026. 03/09/26:- Explore-OSA topline results missed AHI endpoint; showed clinically meaningful blood pressure reduction and favorable safety. 03/12/26:- Explore-OSA topline Ph2 data detailed; AHI endpoint missed; blood pressure reduced; safety favorable; further endpoint analyses planned. 05/06/26:- OSA development reiterated in corporate description; no new Explore-OSA or hypertension outcome milestones disclosed. 08/11/26:- OSA comorbidity focus reiterated; no Explore-OSA clinical milestone disclosed.
Verification
Confirm timing and program details against the company announcement or filing.